HANSOH PHARMA (03692.HK): Small Cell Lung Cancer Product HS-20093 Included in NMPA Priority Review Procedure
NewTimeSpace News: On 11 September 2026, Hansoh Pharmaceutical Group Company Limited (stock code: 03692.HK) announced that, based on positive results from the pivotal Phase III trial ARTEMIS-008, Ruikang Lifutuota Monoclonal Antibody for injection (HS-20093) has been included in the priority review and approval procedure of China's National Medical Products Administration (NMPA) for the indication of small cell lung cancer that has failed platinum-containing treatment on 21 August 2026.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Going Global Weekly: Pharma Out-Licensing Deals Land in Succession as the A-Share Hong Kong Listing Pipeline Expands-20261023
- HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October
- HANSOH PHARMA (03692.HK): Signs ADC Strategic Collaboration and Licence with Roche; US$400mn Upfront, Over US$15bn Milestones
- HANSOH PHARMA (03692.HK): Refiles EU Marketing Application for Aumseqa
- Hansoh(03692.HK): EU revokes Aumolertinib approval, EMA resubmission planned
